Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa intratumoral Ad-SGE-REIC-NS for recurrent malignant glioma
jRCT2063190013Phase 1Active, not recruiting
- Sponsor
- Momotaro-Gene Inc.
- Start
- Sep 2019
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad-SGE-REIC-NS in malignant glioma, sponsored by Momotaro-Gene Inc. Primary endpoints: Safety, Dose-limiting toxicity and 1 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
Ad-SGE-REIC-NS
03
Conditions
malignant glioma
Beyond the preview
Go deeper on jRCT2063190013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063190013.